Department of Public Health, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan; Department of Psychiatry, Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan.
J Affect Disord. 2024 Jan 1;344:473-484. doi: 10.1016/j.jad.2023.10.016. Epub 2023 Oct 18.
Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are commonly prescribed for depression treatment. Animal studies have shown that antidepressants can influence gut microbiota composition and specific bacterial taxa. We aimed to investigate the association between antidepressant use and human gut microbiota composition and functional pathway.
We collected information on antidepressant use, demographic, food patterns, and clinical characteristics through questionnaires and medical records. The gut microbiota profiles of 271 depressive patients were carried out through 16S rRNA gene sequencing. Patients were categorized based on different types of antidepressant use groups for gut microbiota comparisons. MaAsLin2 was performed to evaluate microbiota composition across groups. PICRUSt2 was used to predict microbiota functional pathways.
Patients taking SSRIs or SNRIs had a lower microbiota diversity. We found seven taxa abundances (Turicibacter, Barnesiella, Lachnospiraceae_ND3007_group, Romboutia, Akkermansia, Dialister, Romboutia and Fusicatenibacter) differed in patients with various types of antidepressants compared with those without antidepressant treatments (p < 0.05). Turicibacter inversely correlated with depression severity in SSRIs or SNRI users (r = -0.43, p < 0.05). Top identified pathways were related to compound fermentation and biosynthesis in microbiota function.
Antidepressant usage, especially SSRIs and SNRIs, associates with changes in gut microbiota composition and specific taxa. Given our study's preliminary cross-sectional nature, further research is warranted to comprehend the relationship between antidepressant use, treatment response, and gut microbiota, aiming to enhance therapeutic interventions in the future.
抗抑郁药，特别是选择性 5-羟色胺再摄取抑制剂（SSRIs）和 5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRIs），常用于治疗抑郁症。动物研究表明，抗抑郁药会影响肠道微生物群落组成和特定细菌分类群。我们旨在研究抗抑郁药使用与人类肠道微生物群落组成和功能途径之间的关系。
我们通过问卷和病历收集了抗抑郁药使用、人口统计学、饮食模式和临床特征信息。通过 16S rRNA 基因测序对 271 名抑郁症患者的肠道微生物群进行了分析。根据不同类型的抗抑郁药使用情况对患者进行分组，以进行肠道微生物群比较。使用 MaAsLin2 评估组间微生物群落组成。使用 PICRUSt2 预测微生物群落功能途径。
服用 SSRIs 或 SNRIs 的患者肠道微生物多样性较低。与未接受抗抑郁治疗的患者相比，我们发现 7 种细菌分类群丰度（Turicibacter、Barnesiella、Lachnospiraceae_ND3007_group、Romboutia、Akkermansia、Dialister、Romboutia 和 Fusicatenibacter）在使用各种类型抗抑郁药的患者中存在差异（p<0.05）。Turicibacter 与 SSRIs 或 SNRIs 使用者的抑郁严重程度呈负相关（r=-0.43，p<0.05）。鉴定出的主要功能途径与微生物群落中化合物发酵和生物合成有关。
抗抑郁药的使用，特别是 SSRIs 和 SNRIs，与肠道微生物群落组成和特定细菌分类群的变化有关。鉴于我们研究的初步横断面性质，需要进一步研究以了解抗抑郁药使用、治疗反应和肠道微生物群之间的关系，旨在未来增强治疗干预措施。
